Rigel has partnered with numerous leading pharmaceutical companies including Grifols, Kissei, and Lilly, among others.1
Along with our commercial business, we continue to explore opportunities to create value through strategic collaborations with pharmaceutical and biotechnology companies that align with our commitment to bringing new therapies to patients with unmet medical needs.
1. Rigel also has partnerships with BerGenBio (bemcentinib) and Daiichi Sankyo (milademetan)